Latest news with #JBPharma
Economic Times
5 days ago
- Business
- Economic Times
Novartis offers payment plan for high-cost heart medicine
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Mumbai: In a first-of-its-kind pricing strategy in the pharmaceutical industry, Swiss drug major Novartis has introduced a financing scheme for its cholesterol lowering drug brand Sybrava (inclisiran) in India, as the company looks to expand the adoption of the new generation heart drug that has so far been restricted due to its high has tied up with Indian payment technology company Pine Labs to offer a monthly instalment scheme for the twice-a-year treatment of the injectable drug used to reduce levels of low-density lipoprotein cholesterol (LDL-C), commonly called bad cholesterol."We have recently launched a zero-interest EMI scheme with Pine Labs so that this treatment can be accessible to more patients," Amitabh Dube, country president & MD, Novartis India, said in an exclusive interview with instalment is priced at Rs 15,000-16,000. "The first is a loading dose and the second dose is after 90 days, and then after 180 days. It will be a rolling cycle," said per cardiologists, Novartis has come up with a one-on-one scheme where the second injection will be free on purchase of the first a patient has to pay full value of the first dosage through equated monthly drug was priced at Rs 1.2 lakh per injection when it was launched in January 2024. In the US, sold under brand Leqvio, it is priced at $3,373.4 per dose (about Rs 2.9 lakh).More than 3,000 patients have currently been put on the drug in expand the reach for inclisiran, Novartis has also entered into marketing tie-ups with Mankind Pharma , JB Pharma and Lupin Mankind, which sells inclisiran under brand Crenzlo, is also evaluating possibilities in terms of patient assistance programmes that can make the drug more affordable to the eligible patients in India, said Atish Majumdar, senior president-sales and marketing. Lupin has launched the drug under Tilpazan, while JB Pharma's brand is and JB Pharma did not respond to ET's query until press time on the one year since April 2024, inclisiran recorded sales of Rs 7.7 crore among all three partners, according to data from is not a replacement for statins, the most commonly used class of medications to lower cholesterol, but can be recommended as a line of treatment when statins do not work or if a person is statin intolerant. However, top cardiologists are divided over the widespread prescribing of the opine it is another addition to their armament of treatment. "It is a very important drug that has come into the market. It has the potential to be a very big game changer for blockages," said Dr Nihar Mehta, associate director, Department of Structural Heart Diseases, Jaslok Hospital & Research others said its usage will be for a limited number of patients. Dr Ganesh Kumar AV, director of cardiology at LH Hiranandani Hospital Powai in Mumbai, said: "The medicine is good but it is being overused. With the right usage there are not many patients who need it. My usage of inclisiran has not been much over the last one year; maybe less than 10 out of the about 2,000 patients with coronary artery diseases I treated".
Time of India
5 days ago
- Business
- Time of India
Novartis offers payment plan for high-cost heart medicine
Mumbai: In a first-of-its-kind pricing strategy in the pharmaceutical industry, Swiss drug major Novartis has introduced a financing scheme for its cholesterol lowering drug brand Sybrava (inclisiran) in India, as the company looks to expand the adoption of the new generation heart drug that has so far been restricted due to its high pricing. Novartis has tied up with Indian payment technology company Pine Labs to offer a monthly instalment scheme for the twice-a-year treatment of the injectable drug used to reduce levels of low-density lipoprotein cholesterol (LDL-C), commonly called bad cholesterol. "We have recently launched a zero-interest EMI scheme with Pine Labs so that this treatment can be accessible to more patients," Amitabh Dube, country president & MD, Novartis India, said in an exclusive interview with ET. Each instalment is priced at Rs 15,000-16,000. "The first is a loading dose and the second dose is after 90 days, and then after 180 days. It will be a rolling cycle," said Dube. As per cardiologists, Novartis has come up with a one-on-one scheme where the second injection will be free on purchase of the first dose. However, a patient has to pay full value of the first dosage through equated monthly instalment. The drug was priced at Rs 1.2 lakh per injection when it was launched in January 2024. In the US, sold under brand Leqvio, it is priced at $3,373.4 per dose (about Rs 2.9 lakh). More than 3,000 patients have currently been put on the drug in India. To expand the reach for inclisiran, Novartis has also entered into marketing tie-ups with Mankind Pharma , JB Pharma and Lupin . Mankind, which sells inclisiran under brand Crenzlo, is also evaluating possibilities in terms of patient assistance programmes that can make the drug more affordable to the eligible patients in India, said Atish Majumdar, senior president-sales and marketing. Lupin has launched the drug under Tilpazan, while JB Pharma's brand is Izirize. Lupin and JB Pharma did not respond to ET's query until press time on Monday. In the one year since April 2024, inclisiran recorded sales of Rs 7.7 crore among all three partners, according to data from PharmaTrac. Inclisiran is not a replacement for statins, the most commonly used class of medications to lower cholesterol, but can be recommended as a line of treatment when statins do not work or if a person is statin intolerant. However, top cardiologists are divided over the widespread prescribing of the drug. Some opine it is another addition to their armament of treatment. "It is a very important drug that has come into the market. It has the potential to be a very big game changer for blockages," said Dr Nihar Mehta, associate director, Department of Structural Heart Diseases, Jaslok Hospital & Research Centre. However, others said its usage will be for a limited number of patients. Dr Ganesh Kumar AV, director of cardiology at LH Hiranandani Hospital Powai in Mumbai, said: "The medicine is good but it is being overused. With the right usage there are not many patients who need it. My usage of inclisiran has not been much over the last one year; maybe less than 10 out of the about 2,000 patients with coronary artery diseases I treated".
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
JB Pharma Q4 results: Profit up 15% to ₹145.6 cr; revenue rises 10%
JB Chemicals and Pharmaceuticals reported a 15 per cent year-on-year (Y-o-Y) increase in net profit for Q4 FY25, reaching ₹145.6 crore, while revenue from operations rose 10 per cent Y-o-Y to ₹949.4 crore. Sequentially, net profit declined 10.3 per cent, while revenue fell 1.4 per cent. For the full financial year (FY25), consolidated net profit rose 19.3 per cent to ₹659.5 crore, and revenue from operations increased 12.4 per cent to ₹3,918 crore. Nikhil Chopra, CEO and wholetime director of JB Pharma, said: 'We have closed the financial year FY25 on a strong note, in line with our strategic intent. Our domestic business continues to be one of the fastest growing in the Indian Pharmaceutical Market (IPM). With 75 per cent of India branded formulations sales in progressive, faster-growing segments, we are confident in sustained strong performance going forward.' The stock rose 1.94 per cent to ₹1,610.50 apiece on the BSE. The results were announced after market hours on Wednesday. In Q4, the company's domestic business registered 11 per cent Y-o-Y growth to ₹519 crore. According to IQVIA data, JB Pharma grew 13 per cent Y-o-Y in the quarter, nearly double the Indian Pharmaceutical Market (IPM) growth of 7 per cent. Excluding its ophthalmology portfolio, JB Pharma's growth stood at 12 per cent. Prescription volumes rose 7 per cent Y-o-Y during the quarter. The chronic portfolio recorded strong growth of 16 per cent, while the acute segment grew 10 per cent, as per IQVIA. The ophthalmology segment was a standout performer, growing 22 per cent Y-o-Y to ₹56 crore, compared to ₹46 crore a year earlier. The international business delivered revenue of ₹430 crore in Q4 FY25, up 9 per cent Y-o-Y. Within this, the international formulations business rose 6 per cent to ₹282 crore, driven by double-digit growth in markets like Russia and in the branded generics export segment. JB Pharma's contract development and manufacturing (CDMO) business posted 18 per cent growth during the quarter, with revenue of ₹129 crore and a robust order book for the coming quarters. However, the active pharmaceutical ingredient (API) business remained muted, contributing ₹19 crore in sales. The combined share of the domestic and CDMO businesses increased to 69 per cent of overall revenue, up from 55 per cent in FY21. The domestic business grew 20 per cent annually to ₹2,269 crore, led by sustained demand across therapeutic areas. Excluding ophthalmology, the domestic portfolio registered 13 per cent growth. JB Pharma's international business rose 4 per cent to ₹1,649 crore in FY25, with Russia and branded generics exports recording healthy double-digit growth. The CDMO segment also delivered strong performance in the second half of the fiscal.
